

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/06		A1	(11) International Publication Number: WO 95/31966 (43) International Publication Date: 30 November 1995 (30.11.95)
(21) International Application Number: PCT/US95/06236 (22) International Filing Date: 18 May 1995 (18.05.95) (30) Priority Data: 08/246,868 20 May 1994 (20.05.94) US 08/322,827 13 October 1994 (13.10.94) US 08/329,730 26 October 1994 (26.10.94) US (71) Applicant: NOVAVAX, INC. [US/US]; 12111 Parklawn Drive, Rockville, MD 20852 (US). (72) Inventor: WRIGHT, D., Craig; 14740 Maine Cove Terrace, Gaithersburg, MD 20878 (US). (74) Agents: LOREN, Ralph, A. et al.; Lahive & Cockfield, 60 State Street, Boston, MA 02109 (US).			(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report.</i>
(54) Title: ANTIMICROBIAL OIL-IN-WATER EMULSIONS			
(57) Abstract <p>An antimicrobial oil-in-water emulsion comprising an agent selected from the group consisting of glycerol monooleate, glycerol trioleate, glycerol monolaurate, and glycerol dilaurate as the primary emulsifier and a cationic halogen-containing compound having a C₁₂-C₁₆ chain as a positive charge producing agent is disclosed. The emulsion can optionally further include a sterol, preferably phytosterol. Preferred cationic halogen-containing compounds having a C₁₂-C₁₆ chain for use in the invention include cetylpyridinium chloride, cetylpyridinium bromide, cetyltrimethylammonium bromide, cetyldimethylethylammonium bromide, and benzalkonium chloride. The antimicrobial emulsion can be used in the form of a pharmaceutical preparation to inhibit the growth of a wide variety of infectious pathogens, including bacteria, fungi, and viruses.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Antimicrobial Oil-In-Water Emulsions

Background of the Invention

5 The present invention relates to an antimicrobial lipid-containing oil-in-water emulsion which inactivates infectious pathogens upon contact.

10 It is known that if a water-immiscible liquid phase is mixed into an aqueous phase by mechanical agitation, for example, by means of an ultra-disperser, the stability of the resulting oil-in-water dispersion most frequently requires the addition of an emulsifying agent, the molecules of which are adsorbed onto the surface of the oil droplets to form a kind of continuous membrane which prevents direct contact between two adjacent droplets. The drops of oil can further contain substances soluble in an organic medium, such as a sterol.

15 In addition to discrete oil droplets dispersed in an aqueous phase, oil-in-water emulsions can also contain other lipid structures, such as small lipid vesicles (i.e., lipid spheres which often consist of several substantially concentric lipid bilayers separated from each other by layers of aqueous phase), micelles (e.g., amphiphile molecules in small clusters of 50-200 molecules arranged so that the polar head groups face outward toward the aqueous phase and the apolar tails are sequestered inward away from the aqueous phase), or lamellar phases (lipid dispersions in which each particle consists of parallel glycerol ester bilayers separated by thin films of water). These lipid structures are formed as a result of hydrophobic forces which drive apolar residues (i.e., long hydrocarbon chains) away from water.

25 The portals of entry of pathogenic bacteria, viruses or fungi are predominantly the skin and mucus membranes, and upper and lower respiratory tracts. The first step in any infection is attachment or colonization on skin or mucus membranes with subsequent invasion and dissemination of the infectious pathogen. Accordingly, an object of the present invention is to provide an antimicrobial emulsion which inactivates infectious pathogens on contact by disrupting their membrane structures.

Summary of the Invention

35 The present invention provides a stable antimicrobial oil-in-water emulsion for inactivating infectious pathogens upon contact. The emulsion comprises positively charged droplets of a lipid-containing oily "discontinuous phase" dispersed in an aqueous "continuous phase". It is believed that the oily discontinuous phase inactivates infectious pathogens by disrupting their membrane structure. The emulsion has microbicidal activity against a broad spectrum of bacteria, viruses and yeasts.

The antimicrobial emulsion of the present invention consists primarily of positively charged droplets of an oily discontinuous phase dispersed in an aqueous continuous phase, such as water. The discontinuous phase contains a glycerol ester selected from the group consisting of glycerol monooleate (GMO), glycerol trioleate (GTO), glycerol monolaurate (GMO), and glycerol dilaurate (GDL) and a cationic halogen-containing compound, preferably one having a C₁₂-C₁₆ chain as a positive charge producing agent. The droplets can further contain a sterol, such as cholesterol or phytosterol. The droplets appear to bind to negatively charged proteins contained in bacterial, viral, or fungal membranes, thereby disrupting the membrane structure and irradiating the pathogen.

Antimicrobial emulsions of the present invention are non-toxic and safe, for example, when swallowed, inhaled, or applied to the skin. This result is unexpected since many cationic halogen-containing compounds having a C₁₂-C₁₆ chain are extremely toxic if administered alone. For example, cetylpyridinium chloride (CPC), the preferred cationic halogen-containing compound of the invention, causes severe irritation and damage to tissues of the upper respiratory tract, mucous membranes and skin. However, when administered in the form of an emulsion of the invention, no such adverse effects occur. Furthermore, the emulsions of the invention are stable when heated or exposed to significant levels of acid and base.

The positive charge of the oily discontinuous phase is provided by a cationic halogen-containing compound having a C₁₂-C₁₆ chain. In a preferred embodiment, the cationic halogen-containing compound having a C₁₂-C₁₆ chain is selected from the group consisting of cetylpyridinium chloride (CPC), cetylpyridinium bromide (CPB), cetyltrimethylammonium bromide (CTAB), and cetyldimethylethylammonium bromide (CDEAB). Other cationic halogen-containing compounds having a C₁₂-C₁₆ chain which can be used include, for example, cetyltrimethylammonium chloride, cetylbenzyltrimethylammonium chloride, cetyltributylphosphonium bromide, dodecyltrimethylammonium bromide, and tetradecyltrimethylammonium bromide.

The oily discontinuous phase can further contain at least one sterol selected from the group consisting of cholesterol, cholesterol derivatives, hydrocortisone, phytosterol, and mixtures thereof. The term "cholesterol derivatives," as used herein, includes but is not limited to sulfate and phosphate derivatives of cholesterol. Preferred sterols include phytosterols, such as soya sterol.

Oils useful in forming antimicrobial oil-in-water emulsions of the present invention include a broad spectrum of water-immiscible materials, such as soybean oil, avocado oil, squalene oil, sesame oil, olive oil, canola oil, corn oil, rapeseed oil, safflower oil, sunflower

oil, fish oils, flavor oils, water insoluble vitamins, and mixtures thereof. In a preferred embodiment of the invention, the oil is a scented or flavored oil such as peppermint oil.

5 In another embodiment of the invention, at least a portion of the emulsion may be in the form of lipid structures including, but not limited to, unilamellar, multilamellar, and paucilamellar lipid vesicles, micelles, and lamellar phases.

10 The antimicrobial emulsions of the present invention can be used, for example, in pharmaceutical preparations (e.g., creams, solutions and suspensions) to inhibit the growth of a wide variety of infectious pathogens, including bacteria, viruses, and fungi. Accordingly, the present invention also provides an antimicrobial preparation suitable for pharmaceutical administration made up of an antimicrobial emulsion of the invention and a pharmaceutically acceptable carrier. The preparation can be applied topically to skin surface areas, mucus membranes, or oral surfaces, for example, as a cream, gel, spray, mouthwash, or deodorant to
15 treat or prevent bacterial infections such as *Propionibacterium acnes*, *Neisseria gonorrhea*, *Streptococcus*, and *Staphylococcus epidermidis*. Alternatively, the preparation can be administered internally by, for example, oral or intravenous administration. Such systemic administration of the preparation can be used, for example, to inactivate pathogenic microorganisms, e.g., bacteria such as *Helicobacter pylori*, and viruses, particularly envelope
20 viruses. In a preferred embodiment of the invention, the preparation is administered orally to an individual to treat infection by HIV.

Accordingly, the present invention further provides a method for inhibiting the growth of an infectious pathogen by topical or systemic administration of the antimicrobial
25 emulsion of the invention.

Detailed Description of the Invention

30 The present invention relates to a stable antimicrobial oil-in-water emulsion made of positively charged droplets of an oily discontinuous phase dispersed in an aqueous continuous phase.

35 The term "antimicrobial," as used herein, means having the ability to inactivate infectious pathogens. The term "inactivate", as used herein, includes but is not limited to, killing or inhibiting growth of the organism. The term "infectious pathogen", as used herein, includes, but is not limited to, fungi, viruses, bacteria, and parasites. The antimicrobial emulsion of the present invention inactivates a wide variety of infectious pathogens. It appears that inactivation is achieved by disruption of the membrane structure of the pathogen by the components of the oily discontinuous phase.

The term "emulsion," as used herein, includes both classic oil-in-water dispersions or droplets, as well as other lipid structures which can form as a result of hydrophobic forces which drive apolar residues (i.e., long hydrocarbon chains) away from water and drive polar head groups toward water, when a water immiscible oily phase is mixed with an aqueous phase. These other lipid structures include, but are not limited to, unilamellar, paucilamellar, and multilamellar lipid vesicles, micelles, and lamellar or hexagonal phases. These other lipid structures also contain a glycerol ester selected from the group consisting of glycerol monooleate (GMO), glycerol trioleate (GTO), glycerol monolaurate (GML), and glycerol dilaurate (GDL) as the primary emulsifier, and a dodacyl to hexadecyl cationic halogen-containing compound as a positive charge producing agent. These other lipid structures can also further include at least one sterol, preferably a phytosterol. In a preferred embodiment of the invention, GMO is used as the primary emulsifier. The term "primary emulsifier", as used herein, refers to the emulsifier which constitutes the greatest proportion by weight of any single emulsifier contained in the oily discontinuous phase.

Antimicrobial oil-in-water emulsions of the present invention can be formed using classic emulsion forming techniques which are well known in the art. In brief, the lipid-oil phase is mixed with the aqueous phase under relatively high shear forces to obtain an oil-in-water emulsion containing oil droplets which are approximately 1 micron in diameter. More particularly, a positively charged lipid-containing oily discontinuous phase is formed by blending (a) an oil carrier; (b) a glycerol ester selected from the group consisting of GMO, GTO, GML, or GDL; and (c) a cationic halogen-containing compound having a C₁₂-C₁₆ chain, along with any other compatible glycerol esters or emulsifiers, such as Polysorbate 60, and any sterols or other lipophilic materials to be incorporated into the lipid-oil phase.

Once the lipid-oil phase is formed, it is heated and blended with an aqueous phase (e.g., water, saline, or any other aqueous solution which can hydrate the lipids) on a volume to volume basis ranging from about 1:4 to 1:2, preferably about 1:3 lipid-oil phase to aqueous phase. The lipid-oil and aqueous phases can be blended using any apparatus capable of producing the high shear mixing forces, including, for example, a french press, a NovamixTM lipid vesicle maker (IGI Inc., Buena N.J.), a syringe mixer, or, alternatively by hand using two syringes as described in U.S. Patents Nos. 4,895,452 and 4,911,928, the teachings of which are incorporated by reference herein.

Antimicrobial oil-in-water emulsions of the present invention provide the advantage of being stable in the presence of heat, acid, or base. For example, as shown below in Example 7, emulsions of the invention are not significantly altered or broken down when

boiled or exposed to 1N nitric acid or 1N sodium hydroxide. This stability makes the emulsions suitable for pharmaceutical administration, even internal administration.

Antimicrobial oil-in-water emulsions of the present invention can be used to
5 inactivate a variety of infectious pathogens upon contact. As described in the examples
below, microbes which are inactivated by the present invention include a wide variety of
bacteria, fungi and viruses. More specifically, for inactivation of bacteria which colonize in
oral or oropharyngeal areas, such as *Streptococcus pneumoniae*, Group A beta-hemolytic
10 *Streptococcus*, *Haemophilus influenzae*, and *Neisseria meningitidis*, the presently disclosed
emulsions can be applied topically, as a spray or mouthwash. For bacteria which colonize in
gastrointestinal areas, such as *Helicobacter pylori*, the emulsions can be administered orally,
for example, as a pill or a liquid. For bacteria and fungi which colonize in the vagina, such as
Neisseria gonorrhoeae, *Gardnerella vaginalis*, Group B *Streptococcus*, and *Candida*
15 *albicans*, the emulsions can be applied topically as a cream, gel, or suppository. The
presently disclosed emulsions can also be used for dermatological application as a cream or
gel to inactivate or prevent infection secondary to *Propionibacterium acnes*, *Staphylococcus*
aureus, *Staphylococcus epidermidis*, and Group B *Streptococcus*. In a preferred embodiment
of the invention, antimicrobial emulsions of the present invention are used to prevent
infection by gram positive bacteria.

20 Antimicrobial oil-in-water emulsions of the present invention can also be used to
inactivate a variety of viruses, particularly enveloped viruses upon contact. For example, the
presently disclosed emulsions can be used for oropharyngeal, oral, venereal, dermatological,
or internal application to inactivate or prevent infection secondary to viruses including
25 *Herpesviridae* (e.g., herpes simplex types 1 and 2, Epstein-Barr virus, cytomegalovirus,
varicella virus, and human herpes virus type 6), *Togaviridae* (e.g., Rubella virus),
Flaviviridae, (e.g., Yellow Fever virus), *Coronaviridae* (e.g., Corona viruses), *Rhabdoviridae*
(e.g., Rabies virus), *Filoviridae* (e.g., Marburg virus), *Paramyxoviridae* (e.g., Measles virus),
Orthomyxoviridae (e.g., Influenza viruses), *Bunyaviridae* (e.g., California encephalitis virus),
30 *Arenaviridae* (e.g., Lymphocytic choriomeningitis virus), *Retroviridae* (e.g., HIV-1), and
Hepadnavirida (e.g., Hepatitis B). The emulsions of the invention can also be used to
inactivate viruses *in vitro*, for example, to disinfect contaminated blood products. In a
preferred embodiment of the invention, the oil-in-water emulsions are used to inactivate HIV.

35 The present invention also provides an antimicrobial preparation suitable for
pharmaceutical administration consisting of the antimicrobial emulsion of the present
invention and a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable
carrier," as used herein, refers to any physiologically compatible carrier for use in
pharmaceutical administration. Use of such media and agents for pharmaceutically active

substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the emulsions of the present invention, use thereof in a pharmaceutical preparation is contemplated.

5 The present invention further provides methods for inhibiting the growth of an infectious pathogen by topical, or systemic administration of the antimicrobial emulsion of the present invention, preferably in the form of a pharmaceutical preparation. The term "topical," as used herein, includes application to mucous membranes, oral surfaces, skin, inner ear surfaces, or the surfaces of any bodily orifice, such as the vagina or rectum. The
10 term "systemic", as used herein, includes any form of internal administration, including but not limited to, oral and intravenous administration.

The following examples will illustrate the efficacy of the invention.

15

EXAMPLES

Example 1 - Preparation of GMO and GMS Oil-in-Water Emulsions

20 In this Example, a series of positively and negatively charged lipid-containing oil-in-water emulsions having either GMO or GMS as the primary emulsifier were formed. Selected emulsions were also characterized with regard to purity, pH and size of oil droplets.

25 Table 1 shows the amount of each chemical component used to form the lipid-oil phase of several charged GMO and GMS oil-in-water emulsions having glycerol monooleate (GMO) or glycerol monostearate (GMS) as the primary emulsifiers, and cetylpyridinium chloride (CPC), cetylpyridinium bromide (CPB), cetyltrimethylammonium bromide (CTAB), or dimethyldioctadecylammonium bromide (DDDAB) as positive charge producing agents, or oleic acid as a negative charge producing agent.

TABLE 1

	GMO/ CPC	GMO/ CPB	GMO/ CTAB	GMS/ DDDAB	GMO/ OLEIC	GMS/ CPC
GMO	3.43 g	3.43 g	3.43 g	-----	3.43 g	-----
GMS	-----	-----	-----	3.43 g	-----	3.43 g
Soya Sterol or cholesterol	0.96 g	0.96 g	0.96 g	0.96 g	0.96 g	0.96 g
Tween 60	0.84 g	0.84 g	0.84 g	0.84 g	0.84 g	0.84 g
Soybean Oil	11 g	11 g	11 g	11 g	11 g	11 g
CPC	130 mg	-----	-----	-----	-----	130 mg
CPB	-----	150 mg	-----	-----	-----	-----
CTAB	-----	-----	140 mg	-----	-----	-----
DDDAB	-----	-----	-----	240 mg	-----	-----
Oleic Acid	-----	-----	-----	-----	108 mg	-----

To prepare the charged emulsions shown above in Table 1, a lipid-oil phase containing approximately 12 to 21% by weight GMO or GMS, 0.8 to 0.9% by weight cationic halogen-containing compound (or 0.7% by weight oleic acid), 67 to 80% by weight carrier oil such as soybean oil, 3 to 5% by weight Tween 60 (Polyoxyethylene 20 sorbitan monostearate), and 3 to 6% by weight soya sterol was heated for approximately one hour at 86°C. The lipid-oil phase was then blended with an aqueous phase containing water at 65°C using a 5 ml syringe machine as described in US Patent No. 4,895,452 on a volume to volume basis of 13 parts lipid-oil to 37 parts water.

Table 2 shows the pH of the emulsions shown in Table 1. Also shown is the size of the lipid-oil droplets of the emulsions measured on a Coulter LS 130 Laser sizing instrument equipped with a circulating waterbath.

TABLE 2

Chemical Components of Emulsion	Charge	pH	Mean Coulter Size in Microns	Mean Coulter Range in Microns
GMO/CPC	Positive	3.72	1.049	0.720-1.401
GMO/CPB	Positive	4.31	0.891	0.680-1.124
GMO/CTAB	Positive	4.82	1.143	0.647-1.358
GMS/DDDAB	Positive	5.86	1.080	0.694-1.532
GMO/Oleic acid	Negative	4.45	1.078	0.738-1.448
GMS/CPC	Positive	3.72	1.047	0.677-1.497

Example 2 - Preparation of 10N GMO Oil-in-Water Emulsions

In this Example, a series of positively charged oil-in-water emulsions were prepared having GMO as the primary emulsifier and a 10 fold higher percentage (10N) of cationic halogen-containing compound (cetylpyridinium chloride (CPC), cetylpyridinium bromide (CPB), cetyltrimethylammonium bromide (CTAB), cetyldimethylethylammonium bromide (CDEAB), and benzalkonium chloride (BAC)), as compared with Example 1, as a positive charge producing agent.

Table 3 shows the amount of each chemical component used to form the lipid-oil phase of the positively charged 10N GMO emulsions.

TABLE 3 Positively Charged 10N Emulsions

Chemical Components of Emulsion	GMO/ CPC	GMO/ CPB	GMO/ CTAB	GMO/ CDEAB	GMO/ BAC
GMO	3.43 g	3.43 g	3.43 g	3.43g	3.43 g
Soya Sterol or cholesterol	0.96 g	0.96 g	0.96 g	0.96 g	0.96 g
Tween 60	0.84 g	0.84 g	0.84 g	0.84 g	0.84 g
Soybean Oil	11 g	11 g	11 g	11 g	11 g
CPC	1.3 g	-----	-----	-----	-----
CPB	-----	1.5 g	-----	-----	-----
CTAB	-----	-----	1.4 g	-----	-----
CDEAB	-----	-----	-----	1.3 g	-----
BAC	-----	-----	-----	-----	1.3 g

To prepare the 10N emulsions shown above in Table 3, a lipid-oil phase containing approximately 19% by weight GMO, 62% by weight carrier oil such as soybean oil, 4.7% by weight Tween 60 (Polyoxyethylene 20 sorbitan monostearate), 5.4% by weight soya sterol, and 7.4 to 8.4% by weight cationic detergent was heated for approximately one hour at 86°C. The lipid-oil phase was then blended with an aqueous phase containing water at 65°C using a 5 ml syringe machine (as described in U.S. Patent No. 4,895,452, the teachings of which are incorporated by reference herein) on a volume to volume basis of 13 parts lipid-oil to 37 parts water.

**Example 3 - Microbicidal Activity of GMO and GMS Oil-in-Water Emulsions
Against *Staphylococcus aureus* type 8**

In this Example, the microbicidal activities of each of the GMO and GMS emulsions shown in Table 1 were compared. For this purpose, the ability of each of the emulsions to
5 kill *Staphylococcus aureus* type 8 was tested as follows:

Bacteria were inoculated into liquid media (Trypticase soy broth or Schaedler's broth) and incubated at 37°C for 1-7 hours. An optical density at a wavelength of 650 nm and a quantitative culture were then performed on each broth culture. One milliliter of each
10 bacterial broth was then mixed with one milliliter of emulsion, or water as a control, for 10 or 30 minutes. Quantitative cultures were then performed in duplicate on each mixture. Plates containing bacteria were incubated at 37°C for 18 hours and then counted.

The percentage of bacteria killed was then determined by the following equation.

$$15 \quad \% \text{ kill} = \frac{(A - B)}{A} \times 100$$

A = The total number of bacteria inoculated

B = The total number counted after mixing with an emulsion
20

Table 4 lists the percentages of *Staphylococcus aureus* type 8 killed by each emulsion or water after a 10 or 30 minute incubation with 2×10^7 bacteria.

TABLE 4

Chemical Components of Preparation	% Inactivate After a 10 Minute Incubation	% Inactivate After a 30 Minute Incubation
GMO/CPC	100	100
GMO/CPB	100	100
GMO/CTAB	99.99	99.99
GMO/DDDAB	65	0
GMO/Oleic acid	0	0
GMS/CPC	65	0
Control alone	50	0

25

From Table 4 one can see that the positively charged glycerol monooleate (GMO) emulsions inactivate *Staphylococcus aureus* type 8 while the positively charged glycerol monostearate (GMS/CPC) emulsion fails to inactivate. In addition, only the cationic compounds having a C₁₂-C₁₆ chain containing either chloride or bromide, i.e., CPC, CPB or

CTAB, and not the dioctadecyl cationic compound (DDDAB) or oleic acid (having a negative charge), were associated with significant microbicidal activity. The inactivation of this bacterium, *Staphylococcus aureus*, is therefore more effective using GMO emulsions containing a chloride or bromide containing cationic compound having a C₁₂-C₁₆ chain.

5

In order to determine the effect of varying the concentration of the charge producing agent in the emulsions of the invention, GMO emulsions containing different concentrations of CPC were also tested for antimicrobial activity against *Staphylococcus aureus* type 8. Table 5 shows percentages of *Staphylococcus aureus* type 8 killed after a 10 or 30 minute incubation of the GMO emulsions with 10⁷ bacteria.

10

TABLE 5

Chemical Components of Emulsion	Initial Innoculum of Staphylococcus Aureus Type 8	% Inactivate After a 10 Minute Incubation	% Inactivate After a 30 Minute Incubation
GMO/CPC	10,000,000 CFU [1.8 mg/ml emulsion]	100	100
GMO/CPC	10,000,000 CFU [0.9 mg/ml emulsion]	99.5	100
GMO/CPC	10,000,000 CFU [0.45 mg/ml emulsion]	54	99.5
GMO/CPC	10,000,000 CFU [0.23 mg/ml emulsion]	39	32
GMO/CPC	10,000,000 CFU [0.028 mg/ml emulsion]	0	0
GMO	10,000,000 CFU	0	0
GMO/Oleic acid	10,000,000 CFU	0	0
Water alone	10,000,000 CFU	10	0

Table 5 demonstrates that *Staphylococcus aureus* type 8 bacteria were sensitive to the microbicidal action of the GMO/CPC emulsion at CPC concentrations of greater than 0.23 mg/ml of emulsion.

5

Example 4 - Microbicidal Activity of GMO Oil-in-Water Emulsions Against Bacteria and Yeast

In this Example, the ability of the GMO/CPC emulsion formed in Example 1 and shown in Table 1 to kill a variety of bacteria and yeast was tested.

10

The assay described above in Example 3 was used to measure the microbicidal activity of the GMO/CPC emulsion against a number of bacteria and fungi, except for the following changes:

15

Yeast were inoculated into Sabouraud's broth and incubated at 30°C for 6 hours, mixed with the GMO/CPC emulsion for 10 or 30 minutes, plated and incubated at 37 C for 18 hours before counting.

20

P. acnes was grown anaerobically in Schaedler's broth for 24 hours, mixed with emulsion for 10 or 30 minutes, plated on Trypticase soy agar plates with 5% sheep blood and incubated anaerobically for 72 hours prior to counting.

25

G. vaginalis was plated on Trypticase soy agar plates with 5% sheep blood and incubated in 5% CO₂ at 37°C for 72 hours. Colonies were swabbed from plates and inoculated into Schaedler's broth at the density of a 0.5 McFarland standard. This broth/bacterial mixture was then incubated with the emulsion for 10 or 30 minutes and then plated on Trypticase soy agar plates with 5% sheep blood. Plates were incubated for 72 hours in 5% CO₂ at 37°C before counting colonies.

30

35

Table 6 lists the percentage of gram positive bacteria killed after a 10 or 30 minute incubation of the GMO/CPC emulsion with between 10⁵ and 10⁸ bacteria. The listed bacteria can generally be categorized as follows: (a) those which colonize on the skin which include *Staphylococcus aureus* (type 8), *Staphylococcus aureus* (type 5), *Staphylococcus epidermidis* (strain 977), Group B *Streptococcus* (capsular type III), Group A *Streptococcus* (beta-hemolytic), and *Propionibacterium acnes*; (b) those which colonize in the oropharynx which include Group A *Streptococcus* (beta-hemolytic), *Streptococcus pneumoniae* (type 5), and *Streptococcus mutans*; and (c) those which colonize or infect the vagina which include *Gardnerella vaginalis* and Group B *Streptococcus* (capsular type III).

TABLE 6

	Innoculum (CFU)•	% Inactivate after a 10 Minute Incubation	% Inactivate after a 30 Minute Incubation
Gram Positive Bacteria			
<i>Staphylococcus aureus</i> (type 8/bacteremic isolate)	2×10^7	99.99	99.99
<i>Staphylococcus aureus</i> (type 5 bacteremic isolate)	9×10^6	100	99.99
<i>Staphylococcus epidermidis</i> (strain 977)	8×10^5	100	100
Group B <i>Streptococcus</i> (capsular type III)	2.9×10^7	99.99	100
Group A beta-hemolytic (type 1) <i>Streptococcus</i> (ATCC 12344)	3.3×10^7	99.99	99.99
<i>Listeria monocytogenes</i> (type 2) (ATCC 19112)	1.3×10^8	99.99	99.99
<i>Streptococcus pneumoniae</i> (type 5) (ATCC 6305)	6.4×10^7	100	100
<i>Streptococcus mutans</i> (ATCC 25179)	6.5×10^6	96.2	96.8
<i>Propionibacterium acnes</i> (ATCC 6919)	1.2×10^8	100	100
<i>Enterococcus faecalis</i> (ATCC 19433)	3.7×10^7	99.36	99.98
<i>Gardnerella vaginalis</i> (ATCC 14018)	5.5×10^7	100	100
<i>Lactobacillus acidophilus</i> (ATCC 4356)	5.0×10^5	100	100

• CFU = colony forming units

Table 6 demonstrates that all gram positive bacteria which cause significant human clinical infections were exquisitely sensitive to the microbicidal action of the GMO/CPC emulsion.

5

Table 7 shows the percentage of gram negative bacteria killed after a 10 or 30 minute incubation of the GMO/CPC emulsion with between 10^5 and 10^8 bacteria. Included in the table are gram negative bacteria which colonize in the oropharynx, such as *Haemophilus*

influenzae (capsular type b) and *Neisseria meningitidis* type b; the gastrointestinal tract, such as *Helicobacter pylori*; and the vagina, such as *Neisseria gonorrhoeae*.

TABLE 7

		% Inactivate after a 10 Minute Incubation	% Inactivate after a 30 Minute Incubation
Gram Negative Bacteria	Innoculum (CFU)•		
<i>Escherichia coli</i> type O18:K1	2.1×10^7	97.1	96.7
<i>Escherichia coli</i> type O18:K-	3.2×10^7	89.7	99.6
<i>Escherichia coli</i> J5 (epimerase deficient)	3×10^7	94	85
<i>Flavobacterium meningosepticum</i> Group A (ATCC 13253)	2.1×10^6	0	47.6
<i>Klebsiella pneumonia</i> type O12K+	5×10^7	98.3	99.9
<i>Pseudomonas aeruginosa</i> type FD-1	3.8×10^7	99	99
<i>Pseudomonas aeruginosa</i> MEP strain 2192	8×10^6	99.1	97.5
<i>Haemophilus influenzae</i> capsular type b (ATCVC 33533)	1×10^7	99.99	99.99
<i>Neisseria meningitidis</i> type b (ATCC 13090)	1.6×10^8	100	100
<i>Neisseria gonorrhoeae</i> (ATCC 9793)	1.2×10^6	100	100
<i>Helicobacter pylori</i> (ATCC 43504)	3×10^6	100	100
<i>Helicobacter pylori</i> (ATCC 43629)	4.7×10^6	100	100
<i>Helicobacter pylori</i> (ATCC 49503)	2×10^6	100	100
<i>Helicobacter pylori</i> (ATCC 43579)	7×10^6	100	100

5

Table 7 illustrates that at 30 minutes there is inactivation of at least 85% of the innoculum of all gram negative bacteria tested except for *Flavobacterium meningosepticum*. The encapsulated type b *Haemophilus influenzae*, type b *Neisseria meningitidis*, *Neisseria gonorrhoeae*, and *Helicobacter pylori* bacteria, which have relatively rough LPS types compared to the other gram negative bacteria, are exquisitely sensitive to the microbicidal activity of the GMO/CPC emulsion.

10

Table 8 shows the percentage of the two *Candida* species killed after a 10 or 30 minute incubation of the GMO/CPC emulsion with 10^5 yeast.

TABLE 8

Yeast	Innoculum (CFU)	% Inactivate After a 10 Minute Incubation	% Inactivate After a 30 Minute Incubation
<i>Candida albicans</i> (clinical blood isolate)	3.2×10^5	62.5	62.5
<i>Candida tropicalis</i> (clinical blood isolate)	5.4×10^5	100	100

5

Table 8 demonstrates that significant inactivating of the *Candida albicans* species occurs after only a 10-30 minute incubation with the GMO/CPC emulsion.

10 **Example 5 - Microbicidal Activity of 10N GMO Emulsions**

In this Example, the positively charged 10N GMO emulsions formed in Example 2 and shown in Table 3 were tested for microbicidal activity against two gram positive bacteria, *Staphylococcus aureus* type 8 and *Staphylococcus epidermidis*, and two gram negative bacteria, *E. coli* and *Helicobacter pylori*, as follows:

15

To lyophilized cultures of bacteria, 0.5 mL of Schaedler's Broth was added and the entire contents of the vial inoculated to a 5% Sheep blood agar plate (TSA II). Cultures were then incubated in an anaerobic jar with Campy GasPAK at 37°C for 72 hours. Colonies from 72 hour TSA II plates were then innoculated into Schaedler's broth until an 0.5 McFarland
20 Standard was achieved.

A one ml aliquot of the bacterial culture was then mixed with one ml of oil-in-water emulsion for 10 minutes. Quantitative cultures were then performed in duplicate on each mixture, and a quantitative culture was performed on the original broth culture. Plates
25 containing bacteria were incubated at 37°C for 72 hours in an anaerobic jar with Campy GasPaks and then counted. The percentage of bacteria killed were determined by the following equation and the results are shown in Table 9:

$$\% \text{ Kill} = \frac{(A-B)}{A} \times 100$$

30

A

A = The total number of bacteria innoculated

B = The number counted after mixing with an emulsion or liposomes

- 5 Table 9 lists the percentages of each bacterium killed after a 10 minute incubation with the 10N GMO/CPC emulsion from Table 3 with between 10^6 and 10^7 bacteria. The 10N GMO/CPC emulsion was tested in undiluted form and in several dilutions, as indicated in Table 9.

10 **TABLE 9**

Bacterium	Dilution	Trial # 1	Trial # 2
<i>Staphylococcus aureus</i>	Undilute	NT	100.00%
Type 8	1 : 10		99.99%
8 x 10^7 CFU/mL	1 : 20		99.99%
10 minute incubation	1 : 40		99.99%
	1 : 80		96.25%
<i>Staphylococcus epidermidis</i> 977	Undilute	NT	100.00%
	1 : 10		100.00%
9 X 10^6 CFU/mL	1 : 20		100.00%
10 minute incubation	1 : 40		99.98%
	1 : 80		99.97%
<i>Escherichia coli</i>	Undilute	NT	99.99%
Type 02a,2b	1 : 10		99.99%
1 X 10^7 CFU/mL	1 : 20		99.98%
10 minute incubation	1 : 40		94.00%
	1 : 80		50.00%
<i>Helicobacter pylori</i> 43579	Undilute	100.00%	100.00%
10 minute incubation	1 : 10	100.00%	100.00%
Inoculum for Trial #1	1 : 20	100.00%	100.00%
5X 10^6 CFU/ml			
Inoculum for Trial #2	1 : 40	99.00%	99.00%
2X 10^7 CFU/ml			
	1 : 80	99.20%	99.00%

NT = Not Tested on This Date

- 15 Table 9 shows that at 10 minutes there is a greater than 96% inactivation of each bacterium (except for *E. coli* at high dilutions (i.e., 1 : 40 and 1 : 80)) tested with the 10N

GMO/CPC emulsion up to a 1 : 80 dilution. At a dilution of 1 : 10, there is a 99.99-100% inactivation of each bacterium.

5 **Example 6 - Viricidal Activity of GMO Oil-in-Water Emulsions and Fusogenic Lipid Vesicles Against HIV**

In this Example, the viricidal activity of the GMO/CPC emulsion formed in Example 1 and fusogenic lipid vesicles prepared as described below were tested against HIV.

10 To prepare fusogenic lipid vesicles, 94.5 grams of Polyoxyethylene (POE) 2 Stearyl Ether (Brij 72), 0.78 grams of oleic acid, and 36 grams of cholesterol were heated to melting to form a liquid lipid phase. A portion of that lipid phase, 0.53 ml, was then mixed with 0.47 ml of squalene to form 1.0 ml of a lipid-oil phase. This was blended with an aqueous phase containing 4.0 ml of PBS under shear mixing conditions to form the lipid vesicles, as
15 described in U.S. Patent 4,911,928. "Shear mixing conditions", as used herein, means a shear equivalent to a relative flow of 5-50 m/s through a 1mm orifice. On a volume to volume basis, the mixture contained 4 parts diluent to 1 part lipid-oil mixture, or 11.7% lipid to 8.3% oil to 80% diluent.

20 The GMO/CPC emulsion and Brij 72 fusogenic lipid vesicles were assayed for viricidal activity against HIV as follows:

A cell suspension containing 20×10^6 C8166 cells, a HTLV-1 transformed T cell line, in 20 ml of RPMI media containing 10% PBS and 50 $\mu\text{g/ml}$ gentamicin was prepared
25 and divided into 0.4 ml aliquots. A series of viral dilutions (10^{-2} to 10^{-6}) were then made by first mixing 100 microliters of HIV-1_{Mn} 1000 x pelleted virus with either 100 microliters of sterile water or 100 microliters of the GMO/CPC emulsion for 30 minutes at room temperature on a nutator. 1.8 ml of tissue culture medium was then added to each preparation, resulting in a dilution of 10^{-1} . Serial 10-fold dilutions were then performed from
30 10^{-2} to 10^{-6} by taking 150 microliters of the 10^{-1} dilution and serially diluting it out in 1.35 ml of RPMI media five more times.

Two 0.4 ml aliquots of each dilution were then added to the aliquots of C8166 cells, prepared as described above. The samples were incubated at 37°C for either 2, 6 or 24 hours,
35 washed 3 times in phosphate buffered saline, resuspended in fresh medium and each dilution plated in four replicate wells. Cells were fed twice weekly. Cells were observed at 7 and 14 days for cytopathic effects and supernatants were collected to measure levels of p24 as an indication of viral proliferation. Tissue culture infectious dose (TCID-50 (\log_{10})) calculations were then performed based on the measured levels of p24. The results were as follows:

For samples incubated for 2 hours with the GMO/CPC emulsion, there was a 4.5 log virus reduction, as compared with water, in the TCID-50 at 7 days and a 4.25 log virus reduction in the TCID-50 at 14 days.

For samples incubated for 6 hours with the GMO/CPC emulsion, there was a 4.5 log virus reduction, as compared with water, in the TCID-50 at 7 days and a 5 log virus reduction, as compared with water, in the TCID-50 at 14 days.

For samples incubated for 24 hours with the GMO/CPC emulsion, there was a 4.0 log virus reduction, as compared with water, in the TCID-50 at 7 and 14 days; there was a 3.75 and 4.25 log reduction, as compared with Phosphate Buffered Saline, in the TCID-50 at 7 and 14 days, respectively; and there was a 4.0 and 4.5 log reduction, as compared with fusogenic novasomes containing POE 2 Stearyl Ether, in the TCID-50 at 7 and 14 days, respectively.

Overall, this Example demonstrates that GMO/CPC emulsions inactivate 4.0 to 5.0 logs of HIV-1_{Mn} infectivity in C8166 tissue culture assays. These experiments, which can be performed using any enveloped virus, demonstrate the effectiveness of these materials to inactivate viruses such as HIV-1_{Mn}.

Example 7 - Stability of GMO Oil-in-Water Emulsions

In this Example, the GMO/CPC emulsion formed in Example 1 was tested for stability in the presence of heat, acid and base. Table 10 shows the effect of boiling for one hour on breakdown or aggregation of the GMO/CPC emulsion, shows the effects of mixing equal volumes of 1N Nitric acid and GMO/CPC emulsion for two hours on breakdown or aggregation of the GMO/CPC emulsion, and the effects of mixing equal volumes of 1N Sodium hydroxide and GMO/CPC emulsion for two hours on breakdown or aggregation of the GMO/CPC emulsion.

TABLE 10

Chemical Components of Emulsion	Intervention	Mean Coulter Size in Microns	Mean Coulter Range in Microns
GMO/CPC	No boiling	1.008	0.720-1.337
GMO/CPC	Boiling 1 hour	1.167	0.654-1.517
GMO/CPC	No acid treatment	1.008	0.720-1.337
GMO/CPC	1N HNO ₃ for 2 hours	1.062	0.675-1.569
GMO/CPC	No base treatment	1.008	0.720-1.337
GMO/CPC	1N NaOH for 2 hours	0.804	0.658-0.969

Table 10 shows that : (a) boiling for 1 hour does not significantly alter the breakdown or size of the emulsion; (b) 1N Nitric acid exposure for 2 hours does not significantly alter the size or aggregate profile of the CMO/CPC emulsion; and (c) 1N Sodium hydroxide exposure for 2 hours causes a 20% decrease in the mean size of the emulsion without disrupting the emulsion or causing aggregation.

From the above-described Examples 1-7, it is evident that the antimicrobial oil-in-water emulsions of the present invention have significant microbicidal activity against a wide variety of viruses, bacteria and yeast, even at extremely low concentrations of cationic halogen-containing compound, such as CPC. Furthermore, the emulsions of the invention are stable in the presence of heat, acid, and base, making them very suitable for pharmaceutical administration, whether topical, oral or systemic.

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

What is claimed is:

1. An antimicrobial oil-in-water emulsion comprising positively charged droplets of an oily discontinuous phase dispersed in a continuous aqueous phase, the emulsion comprising:
 - 5 a. an oil;
 - b. a glycerol ester; and
 - c. a cationic halogen-containing compound having a C₁₂-C₁₆ chain.
- 10 2. An antimicrobial emulsion of claim 1, wherein the glycerol ester is selected from the group consisting of glycerol monooleate, glycerol trioleate, glycerol monolaurate, and glycerol dilaurate.
- 15 3. An antimicrobial emulsion of claim 1, wherein the oil is selected from the group consisting of soybean oil, squalene oil, sesame oil, olive oil, canola oil, corn oil, rapeseed oil, safflower oil, sunflower oil, fish oils, avocado oil, flavor oils, water insoluble vitamins, and mixtures thereof.
- 20 4. An antimicrobial emulsion of claim 1, wherein the halogen is selected from the group consisting of bromine, chlorine, and fluorine.
- 25 5. An antimicrobial emulsion of claim 1, wherein the cationic halogen-containing compound having a C₁₂-C₁₆ chain is selected from the group consisting of cetylpyridinium chloride, cetylpyridinium bromide, cetyltrimethylammonium bromide, cetyltrimethylammonium chloride, cetyldimethylethylammonium bromide, cetylbenzyltrimethylammonium chloride, cetyltributylphosphonium bromide, dodecyltrimethylammonium bromide, and tetradecyltrimethylammonium bromide.
- 30 6. An antimicrobial emulsion of claim 1, wherein the emulsion further comprises at least one sterol selected from the group consisting of cholesterol, cholesterol derivatives, hydrocortisone, phytosterol, and mixtures thereof.
- 35 7. The antimicrobial emulsion of claim 1, wherein at least a portion of the emulsion is in the form of a positively charged lipid structure selected from the group consisting of unilamellar, multilamellar, and paucilamellar lipid vesicles, micelles, and lamellar phases.
8. An antimicrobial preparation suitable for pharmaceutical administration comprising the antimicrobial emulsion of claim 1 and a pharmaceutically acceptable carrier.

9. An antimicrobial oil-in-water emulsion comprising positively charged droplets of an oily discontinuous phase dispersed in a continuous aqueous phase, the emulsion comprising:

- 5 a. an oil selected from the group consisting of soybean oil, squalene oil, squalane oil, sesame oil, olive oil, canola oil, corn oil, rapeseed oil, safflower oil, sunflower oil, fish oils, avocado oil, flavor oils, water insoluble vitamins, and mixtures thereof;
- b. glycerol monooleate; and
- c. cetylpyridinium chloride.

10

10. An antimicrobial preparation suitable for pharmaceutical administration comprising the antimicrobial emulsion of claim 9 and a pharmaceutically acceptable carrier.

11. A method of inhibiting the growth of an infectious pathogen comprising the step of topical application of an antimicrobial oil-in-water emulsion, said antimicrobial emulsion being in the form of positively charged droplets of an oily discontinuous phase dispersed in a continuous aqueous phase, the emulsion comprising:

- 15 a. an oil;
- b. a glycerol ester; and
- 20 c. a cationic halogen-containing compound having a C₁₂-C₁₆ chain.

12. The method of claim 11, wherein the glycerol ester is selected from the group consisting of glycerol monooleate, glycerol trioleate, glycerol monolaurate, and glycerol dilaurate as the primary emulsifier.

25

13. The method of claim 11, wherein the halogen is selected from the group consisting of bromine, chlorine, and fluorine.

14. The method of claim 11, wherein the cationic halogen-containing compound having a C₁₂-C₁₆ chain is selected from the group consisting of cetylpyridinium chloride, cetylpyridinium bromide, cetyltrimethylammonium bromide, cetyldimethylethylammonium bromide, and benzalkonium chloride.

30

15. The method of claim 11, wherein the oil is selected from the group consisting of soybean oil, squalene oil, sesame oil, olive oil, canola oil, corn oil, rapeseed oil, safflower oil, sunflower oil, fish oils, avocado oil, flavor oils, water insoluble vitamins, and mixtures thereof.

35

16. The method of claim 11, wherein the emulsion further comprises at least one sterol selected from the group consisting of cholesterol, cholesterol derivatives, hydrocortisone, phytosterol, and mixtures thereof.

5 17. The method of claim 11, wherein said topical application comprises oral application.

18. The method of claim 11, wherein said topical application comprises application to a mucous membrane via inhalation.

10 19. The method of claim 11, wherein said topical application comprises vaginal application.

20. The method of claim 11, wherein the infectious pathogen is a bacterium.

15 21. The method of claim 11, wherein the infectious pathogen is a fungus.

22. The method of claim 11, wherein the infectious pathogen is a virus.

20 23. The method of claim 22, wherein the virus is an enveloped virus.

24. The method of claim 23, wherein the enveloped virus is HIV.

25 25. The method of claim 23, wherein the enveloped virus is selected from the group consisting of *Herpesviridae*, *Togaviridae*, *Flaviviridae*, *Coronaviridae*, *Rhabdoviridae*, *Filoviridae*, *Paramyxoviridae*, *Orthomyxoviridae*, *Bunyaviridae*, *Arenaviridae*, *Retroviridae*, and *Hepadnavirida*.

30 26. A method of inhibiting the growth of an infectious pathogen comprising the step of topical application of an antimicrobial oil-in-water emulsion to an area containing the infectious pathogen, the antimicrobial emulsion being in the form of positively charged droplets of an oily discontinuous phase dispersed in a continuous aqueous phase, the emulsion comprising:

35 a. an oil selected from the group consisting of soybean oil, squalane oil, sesame oil, olive oil, canola oil, corn oil, rapeseed oil, safflower oil, sunflower oil, fish oils, avocado oil, flavor oils, water insoluble vitamins, and mixtures thereof;

b. glycerol monooleate; and

c. cetylpyridinium chloride.

27. A method of inhibiting the growth of an infectious pathogen *in vivo* comprising the step of systemically administering to a subject an antimicrobial oil-in-water emulsion, said antimicrobial emulsion being in the form of positively charged droplets of an oily discontinuous phase dispersed in a continuous aqueous phase, the emulsion comprising:

- 5
- a. an oil selected from the group consisting of soybean oil, squalene oil, sesame oil, olive oil, canola oil, corn oil, rapeseed oil, safflower oil, sunflower oil, fish oils, avocado oil, flavor oils, water insoluble vitamins, and mixtures thereof;
 - b. a glycerol ester selected from the group consisting of glycerol
10 monooleate, glycerol trioleate, glycerol monolaurate, and glycerol dilaurate; and
 - c. a cationic halogen-containing compound having a C₁₂-C₁₆ chain selected from the group consisting of cetylpyridinium chloride, cetylpyridinium bromide, cetyltrimethylammonium bromide, cetyldimethylethylammonium bromide, and benzalkonium chloride.

15 28. The method of claim 27, wherein the emulsion further comprises at least one sterol selected from the group consisting of cholesterol, cholesterol derivatives, hydrocortisone, phytosterol, and mixtures thereof.

20 29. The method of claim 27 wherein said step of systemically administering comprises enteral administration.

30. The method of claim 27, wherein the pathogen is selected from the group consisting of bacteria, fungi, and viruses.

25 31. A method of treating an infection by a pathogen in a subject comprising the step of systemically administering to the subject an antimicrobial oil-in-water emulsion comprising positively charged droplets of an oily discontinuous phase dispersed in a continuous aqueous phase, the emulsion comprising:

- 30
- a. an oil;
 - b. glycerol monooleate; and
 - c. cetylpyridinium chloride.

35 32. A method of inactivating an infectious pathogen *in vitro* comprising the step of contacting the pathogen with an antimicrobial oil-in-water emulsion, the emulsion being in the form of positively charged droplets of an oily discontinuous phase dispersed in a continuous aqueous phase, the emulsion comprising:

- a. an oil selected from the group consisting of soybean oil, squalene oil, sesame oil, olive oil, canola oil, corn oil, rapeseed, safflower oil, sunflower oil, fish oils,

petrolatum, avocado oil, triglyceride oils and fats, flavor oils, water insoluble vitamins, and mixtures thereof;

b. a glycerol ester selected from the group consisting of glycerol monooleate, glycerol trioleate, glycerol monolaurate, and glycerol dilaurate; and

5 c. a cationic halogen-containing compound having a C₁₂-C₁₆ chain selected from the group consisting of cetylpyridinium chloride, cetylpyridinium bromide, and cetyltrimethylammonium bromide.

10 33. The method of claim 32, wherein the pathogen is a virus.

34. The method of claim 33, wherein the virus is HIV.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/06

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K/06

US CL : 424/401

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/401

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN-CAS; APS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	US,A, 5,362,494 (Zysman et al) 08 November 1994, column 7-11.	1-34



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A document defining the general state of the art which is not considered to be of particular relevance	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E earlier document published on or after the international filing date	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* &	document member of the same patent family
* O document referring to an oral disclosure, use, exhibition or other means		
* P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

12 JULY 1995

Date of mailing of the international search report

28 JUL 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MACMILLAN/JARVIS

Telephone No. (703) 308-1235